stockportfolio.pro
ArriVent BioPharma, Inc. (AVBP)
Healthcare · Biotechnology · NasdaqGM
ArriVent BioPharma, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-36.91M | $-69.33M | $-80.49M | $-166.31M |
| Net margin | — | — | — | — |
Source: ArriVent BioPharma, Inc. SEC filings (10-K).
Explore 4 years of ArriVent BioPharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AVBP in your portfolio →
ArriVent BioPharma, Inc. financial history by metric
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
ArriVent BioPharma, Inc. — frequently asked questions
What is ArriVent BioPharma, Inc.'s revenue?
ArriVent BioPharma, Inc. (AVBP) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is ArriVent BioPharma, Inc. profitable?
No — AVBP reported a net loss of $-166.31M in fiscal 2025.
What is AVBP's P/E ratio?
ArriVent BioPharma, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does ArriVent BioPharma, Inc. have?
As of fiscal year 2025, AVBP carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ArriVent BioPharma, Inc.'s market cap?
ArriVent BioPharma, Inc. (AVBP) has a market capitalization of about $1.42B, based on the latest data in our nightly-refreshed cache.
When does ArriVent BioPharma, Inc.'s fiscal year end?
AVBP's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from ArriVent BioPharma, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.